UNITED THERAPEUTICS Corp Quarterly Operating Income (Loss) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
UNITED THERAPEUTICS Corp quarterly/annual Operating Income (Loss) history and growth rate from Q1 2010 to Q3 2024.
  • UNITED THERAPEUTICS Corp Operating Income (Loss) for the quarter ending September 30, 2024 was $343M, a 4.92% increase year-over-year.
  • UNITED THERAPEUTICS Corp Operating Income (Loss) for the twelve months ending September 30, 2024 was $1.28B, a 16.3% increase year-over-year.
  • UNITED THERAPEUTICS Corp annual Operating Income (Loss) for 2023 was $1.18B, a 20.9% increase from 2022.
  • UNITED THERAPEUTICS Corp annual Operating Income (Loss) for 2022 was $980M, a 76.2% increase from 2021.
  • UNITED THERAPEUTICS Corp annual Operating Income (Loss) for 2021 was $556M, a 6.35% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.28B $343M +$16.1M +4.92% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $1.26B $320M +$6.5M +2.07% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $1.26B $356M +$71.9M +25.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $1.18B $260M +$84.5M +48.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $1.1B $327M +$12.7M +4.04% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $1.09B $313M +$112M +55.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $976M $284M -$3.6M -1.25% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $980M $176M +$5.8M +3.42% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $974M $314M +$85.6M +37.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $888M $202M -$20.4M -9.18% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $909M $288M +$353M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $556M $170M +$105M +160% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $451M $229M +$7.6M +3.44% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $444M $222M +$81.7M +58.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $362M -$64.8M -$232M -139% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $594M $65.3M +$1.8M +2.84% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-22
Q3 2020 $592M $221M +$37.7M +20.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $554M $141M -$80.9M -36.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $635M $167M +$823M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$188M $63.5M -$68M -51.7% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$120M $183M +$33.8M +22.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 -$153M $221M +$4M +1.84% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-29
Q1 2019 -$157M -$656M -$963M -314% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-29
Q4 2018 $805M $132M -$7.5M -5.4% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $813M $150M -$174M -53.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-30
Q2 2018 $987M $217M +$129M +146% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-31
Q1 2018 $858M $307M +$43.3M +16.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 $815M $139M -$35.2M -20.2% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $850M $324M +$85.2M +35.7% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-31
Q2 2017 $765M $88.5M -$197M -69% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 $962M $264M -$100M -27.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-02
Q4 2016 $1.06B $174M +$19.2M +12.4% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $1.04B $239M -$148M -38.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-25
Q2 2016 $1.19B $285M +$113M +66% Apr 1, 2016 Jun 30, 2016 10-Q 2017-07-27
Q1 2016 $1.08B $364M +$379M Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-26
Q4 2015 $699M $155M -$23.6M -13.2% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-21
Q3 2015 $723M $387M +$419M Jul 1, 2015 Sep 30, 2015 10-Q 2016-10-27
Q2 2015 $303M $172M -$4.52M -2.56% Apr 1, 2015 Jun 30, 2015 10-Q 2016-07-28
Q1 2015 $308M -$14.8M -$231M -107% Jan 1, 2015 Mar 31, 2015 10-Q 2016-04-28
Q4 2014 $539M $179M +$207M Oct 1, 2014 Dec 31, 2014 10-K 2017-02-22
Q3 2014 $332M -$32.2M -$137M -131% Jul 1, 2014 Sep 30, 2014 10-Q 2015-10-27
Q2 2014 $469M $176M +$54M +44.2% Apr 1, 2014 Jun 30, 2014 10-Q 2015-07-28
Q1 2014 $415M $216M +$122M +130% Jan 1, 2014 Mar 31, 2014 10-Q 2015-04-28
Q4 2013 $292M -$28.5M -$157M -122% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-25
Q3 2013 $450M $105M +$23.9M +29.6% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-28
Q2 2013 $426M $122M +$16.7M +15.8% Apr 1, 2013 Jun 30, 2013 10-Q 2014-07-29
Q1 2013 $409M $94M -$12.7M -11.9% Jan 1, 2013 Mar 31, 2013 10-Q 2014-04-29
Q4 2012 $422M $129M +$65.1M +102% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-24
Q3 2012 $357M $80.7M -$22.3M -21.6% Jul 1, 2012 Sep 30, 2012 10-Q 2013-10-29
Q2 2012 $379M $106M -$8.91M -7.78% Apr 1, 2012 Jun 30, 2012 10-Q 2013-07-25
Q1 2012 $388M $107M +$69.9M +190% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-25
Q4 2011 $318M $63.5M +$48.2M +314% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-25
Q3 2011 $270M $103M +$40.5M +64.8% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-01
Q2 2011 $229M $114M +$53.3M +87% Apr 1, 2011 Jun 30, 2011 10-Q 2012-07-26
Q1 2011 $176M $36.8M +$4.56M +14.1% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-26
Q4 2010 $171M $15.4M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-26
Q3 2010 $62.5M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-27
Q2 2010 $61.2M Apr 1, 2010 Jun 30, 2010 10-Q 2011-07-28
Q1 2010 $32.2M Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.